# US 2021/0332386 A1 · Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332386 A1
- Document ID: US20210332386A1
- Status: Published application
- Kind: A1
- Application number: 17/284,284
- Filed: 2019-10-18
- Published: 2021-10-28
- Earliest claimed: 2018-10-19
- Applicants: Ohio State Innovation Foundation
- Inventors: Daniel Gallego-Perez; Silvia Duarte Sanmiguel; Natalia Higuita-Castro; William Carson
- Web page: https://patentgrep.com/patent/US20210332386A1

## CPC

- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/62: DNA sequences coding for fusion proteins
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are MDSC-targeted extracellular vesicles (EVs) loaded with therapeutic cargo, as well as compositions, systems, and methods for making same. Also disclosed herein is an MDSC-targeting ligand, such as a fusion protein containing an MDSC-targeting moiety. Also disclosed are EVs containing the disclosed fusion protein. In some embodiments, the EV is also loaded with a therapeutic cargo. Also disclosed is an EV-producing cell engineered to produce the disclosed EVs. Also disclosed is a method for making the disclosed EVs that involves culturing the disclosed EV-producing cells under conditions suitable to produce EVs.

## Claims

### Claim 1

A fusion protein comprising ICAM1 and an exosomal or lysosomal transmembrane protein.

### Claim 2 (depends on 1)

The extracellular vesicle comprising the fusion protein of claim 1.

### Claim 3 (depends on 2)

The extracellular vesicle of claim 2, further comprising a therapeutic cargo.

### Claim 4 (depends on 3)

The extracellular vesicle of claim 3, wherein the therapeutic cargo comprises miR146a.

### Claim 5 (depends on 3)

The extracellular vesicle of claim 3, wherein the therapeutic cargo comprises Ibrutinib.

### Claim 6 (depends on 1)

A cell comprising a nucleic acid encoding the fusion protein of claim 1.

### Claim 7 (depends on 6)

The cell of claim 6, further comprising a nucleic acid encoding a therapeutic RNA.

### Claim 8 (depends on 6)

A method of producing an extracellular vesicle, comprising culturing the cell of claim 6 under conditions suitable for vesicle secretion, and isolating extracellular vesicles secreted by the cell.

### Claim 9 (depends on 8)

The method of claim 8, further comprising loading the extracellular vesicle with a therapeutic drug.

### Claim 10 (depends on 3)

A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the extracellular vesicle of claim 3.

### Claim 11 (depends on 10)

The method of claim 10, wherein the subject has circulating myeloid-derived suppressor cells (MDSCs).
